PT1529529E - Utilização de, no mínimo, um efector do metabolismo da glutationa em conjunto com ácido alfa-lipóico para o tratamento imunomodulador, imunoestimulador e/ou anti-inflamatório - Google Patents
Utilização de, no mínimo, um efector do metabolismo da glutationa em conjunto com ácido alfa-lipóico para o tratamento imunomodulador, imunoestimulador e/ou anti-inflamatório Download PDFInfo
- Publication number
- PT1529529E PT1529529E PT04027492T PT04027492T PT1529529E PT 1529529 E PT1529529 E PT 1529529E PT 04027492 T PT04027492 T PT 04027492T PT 04027492 T PT04027492 T PT 04027492T PT 1529529 E PT1529529 E PT 1529529E
- Authority
- PT
- Portugal
- Prior art keywords
- thiol
- microm
- effector
- glutathione metabolism
- alpha
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title abstract 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title abstract 4
- 108010024636 Glutathione Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 239000012636 effector Substances 0.000 title abstract 3
- 229960003180 glutathione Drugs 0.000 title abstract 3
- 230000004060 metabolic process Effects 0.000 title abstract 3
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- 235000019136 lipoic acid Nutrition 0.000 title abstract 2
- 229960002663 thioctic acid Drugs 0.000 title abstract 2
- 230000001741 anti-phlogistic effect Effects 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 230000002584 immunomodulator Effects 0.000 abstract 2
- 150000003573 thiols Chemical class 0.000 abstract 2
- 229940123457 Free radical scavenger Drugs 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000011324 bead Substances 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- 230000008260 defense mechanism Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10125882A DE10125882B4 (de) | 2001-05-28 | 2001-05-28 | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1529529E true PT1529529E (pt) | 2009-05-11 |
Family
ID=7686361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04027492T PT1529529E (pt) | 2001-05-28 | 2002-05-27 | Utilização de, no mínimo, um efector do metabolismo da glutationa em conjunto com ácido alfa-lipóico para o tratamento imunomodulador, imunoestimulador e/ou anti-inflamatório |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7429614B2 (enExample) |
| EP (2) | EP1529529B1 (enExample) |
| JP (1) | JP4746258B2 (enExample) |
| AT (2) | ATE429911T1 (enExample) |
| AU (1) | AU2002344178A1 (enExample) |
| DE (3) | DE10125882B4 (enExample) |
| ES (2) | ES2247377T3 (enExample) |
| PT (1) | PT1529529E (enExample) |
| WO (1) | WO2002096398A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303229B4 (de) | 2003-01-28 | 2007-07-26 | Keyneurotek Ag | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
| DE10360954B3 (de) * | 2003-12-23 | 2005-08-18 | Esparma Gmbh | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| JP5785355B2 (ja) * | 2004-11-24 | 2015-09-30 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物における生体異物物質の肝臓クリアランスを改良する方法 |
| US20100099751A1 (en) * | 2008-10-21 | 2010-04-22 | Al-Mulla Fahd | Method of treating diabetes-related vascular complications |
| KR20110103987A (ko) * | 2008-12-01 | 2011-09-21 | 인베이스크 테라퓨틱, 인크. | 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도 |
| CN113244265B (zh) * | 2021-03-23 | 2023-07-14 | 武汉广行科学研究有限公司 | 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03169813A (ja) * | 1989-11-09 | 1991-07-23 | Asta Pharma Ag | 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法 |
| DE4218572A1 (de) * | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
| DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
| DE4420102A1 (de) * | 1994-06-09 | 1995-12-14 | Asta Medica Ag | Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| US6133304A (en) * | 1997-12-23 | 2000-10-17 | Warner-Lambert Company | ACE inhibitor-MMP inhibitor combinations |
| DE19806354B4 (de) * | 1998-02-10 | 2004-09-16 | Bdd Group Holding Ag | Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie |
| JP2000309543A (ja) * | 1999-04-28 | 2000-11-07 | Ajinomoto Co Inc | 抗糖尿病剤 |
| DE10125883A1 (de) * | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
-
2001
- 2001-05-28 DE DE10125882A patent/DE10125882B4/de not_active Expired - Fee Related
-
2002
- 2002-05-27 ES ES02774028T patent/ES2247377T3/es not_active Expired - Lifetime
- 2002-05-27 EP EP04027492A patent/EP1529529B1/de not_active Expired - Lifetime
- 2002-05-27 DE DE50204093T patent/DE50204093D1/de not_active Expired - Lifetime
- 2002-05-27 AU AU2002344178A patent/AU2002344178A1/en not_active Abandoned
- 2002-05-27 WO PCT/EP2002/005811 patent/WO2002096398A2/de not_active Ceased
- 2002-05-27 ES ES04027492T patent/ES2322257T3/es not_active Expired - Lifetime
- 2002-05-27 EP EP02774028A patent/EP1392288B1/de not_active Expired - Lifetime
- 2002-05-27 AT AT04027492T patent/ATE429911T1/de not_active IP Right Cessation
- 2002-05-27 DE DE50213511T patent/DE50213511D1/de not_active Expired - Lifetime
- 2002-05-27 US US10/478,174 patent/US7429614B2/en not_active Expired - Fee Related
- 2002-05-27 PT PT04027492T patent/PT1529529E/pt unknown
- 2002-05-27 AT AT02774028T patent/ATE303145T1/de active
- 2002-05-27 JP JP2002592909A patent/JP4746258B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2322257T3 (es) | 2009-06-18 |
| ES2247377T3 (es) | 2006-03-01 |
| DE10125882A1 (de) | 2002-12-12 |
| JP2004531567A (ja) | 2004-10-14 |
| WO2002096398A3 (de) | 2003-02-27 |
| EP1392288A2 (de) | 2004-03-03 |
| AU2002344178A1 (en) | 2002-12-09 |
| DE50204093D1 (de) | 2005-10-06 |
| ATE429911T1 (de) | 2009-05-15 |
| EP1529529B1 (de) | 2009-04-29 |
| ATE303145T1 (de) | 2005-09-15 |
| DE10125882B4 (de) | 2007-03-29 |
| US20040138311A1 (en) | 2004-07-15 |
| JP4746258B2 (ja) | 2011-08-10 |
| DE50213511D1 (de) | 2009-06-10 |
| EP1529529A1 (de) | 2005-05-11 |
| EP1392288B1 (de) | 2005-08-31 |
| US7429614B2 (en) | 2008-09-30 |
| WO2002096398A2 (de) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6011067A (en) | Antioxidant composition for the treatment of psoriasis and related diseases | |
| WO2003061768A3 (fr) | Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaircir la peau | |
| WO2005011627A3 (en) | Regulation of mammalian keratinous tissue using n-acyl amino acid compositons | |
| WO2006116353A8 (en) | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress | |
| WO2001021159A3 (en) | Pharmaceutical composition of nateglinide and another antidiabetcagent | |
| PL1658039T3 (pl) | Zastosowanie biotyny lub pochodnej biotyny do rozjaśniania skóry i zwalczania plam starczych | |
| WO2004069190A3 (en) | Combination therapy for treating protein deficiency disorders | |
| BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
| WO2008008608A3 (en) | Method of treating and preventing secondary hyperparathyroidism | |
| WO2005094836A3 (en) | Use of loteprednol etabonate for the treatment of dry eye | |
| WO2004000227A3 (en) | Use of thio-oxindole derivatives in treatment of skin disorders | |
| WO2004000230A3 (en) | Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders | |
| PT1529529E (pt) | Utilização de, no mínimo, um efector do metabolismo da glutationa em conjunto com ácido alfa-lipóico para o tratamento imunomodulador, imunoestimulador e/ou anti-inflamatório | |
| BRPI0412424A (pt) | composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas | |
| WO2004100884A3 (en) | Oral care methods and products | |
| EA200701017A1 (ru) | Применение рибозы-цистеина для лечения гипоксии | |
| EP0714276A1 (fr) | Composition contre la chute des cheveux et la fragilite des ongles | |
| WO2012120462A2 (en) | Oral supplementation for the reversal of human hair canities | |
| EP1719774A4 (en) | PREVENTIVE BZW. THERAPEUTIC AGENT AGAINST DIABETIC MAKULOPATHY | |
| AU2003257473A1 (en) | Modified amino acid for the inhibition of platelet aggregation | |
| WO2008099804A1 (ja) | 糖尿病白内障の治療剤 | |
| WO2006013193A8 (en) | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | |
| WO2006028991A3 (en) | Composition and method for prevention or treatment of stomatits | |
| WO2007047893A3 (en) | Use of dasatinib for the treatment of bone metastasis | |
| PL1664044T3 (pl) | Monohydrat soli sodowej s-tenatoprazolu i jego zastosowanie jako inhibitora pompy protonowej |